Fortress Biotech, Inc.
FBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001429260
No open-market purchases or sales by Fortress Biotech, Inc. insiders were filed in the last 90 days; 55 institutions reported holding it in 13F filings for Q2 2026, worth $17.7M in total; no superinvestor holds it.
Other share classesFBIOP
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +3 vs. previous quarter
- 55
- 13F valueReported value at the end of Q2 2026
- $17.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding FBIO, Q2 2026
No superinvestor reported holding FBIO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Fortress Biotech, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2024 (view filing)4:45 PM ET | Sep 23 | 2 days | Rosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMAN | PPurchaseCommon stock, par value $0.001 | +763.4K | $1.84 | +$1.40M | +26.4%3.66M after | |
| Sep 25, 2024 (view filing)4:45 PM ET | Sep 23 | 2 days | Rosenwald Lindsay A MDPRESIDENT, CEO & CHAIRMAN | PPurchase | +763.4K | $0.125 | +$95.4K | –763.4K after | Derivative |
| Jul 15, 2024 (view filing) | Jul 11 | 4 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.48 | +$37.4K | +4.1%127.5K after | |
| Jul 12, 2024 (view filing) | Jul 10 | 2 days | Jin DavidChief Financial Officer | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +500 | $7.50 | +$3.75K | New position500 after | |
| Jul 11, 2024 (view filing) | Jul 9 | 2 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.39 | +$37.0K | +4.3%122.5K after | |
| Jul 10, 2024 (view filing) | Jul 8 | 2 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseSERIES A CUMULATIVE PERPETUAL PREFERRED STOCK | +5.00K | $7.35 | +$36.8K | +4.4%117.5K after | |
| Jul 1, 2024 (view filing) | Jun 28 | 3 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseCOMMON STOCK, PAR VALUE $0.001 | +20.0K | $1.64 | +$32.8K | +0.7%2.89M after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseCOMMON STOCK, PAR VALUE $0.001 | +10.0K | $1.76 | +$17.6K | +0.3%2.87M after | |
| May 20, 2024 (view filing) | May 20 | Same day | Klein DovDirector | SSaleCOMMON STOCK, PAR VALUE $0.001 | −10.0K | $1.89 | −$18.9K | −15.8%53.4K after | |
| Jan 9, 2024 (view filing) | Jan 5 | 4 days | Rosenwald Lindsay A MDPresident, CEO & Chairman | PPurchaseCOMMON STOCK, PAR VALUE $0.001 | +50.0K | $2.38 | +$119.0K | +1.8%2.86M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Fortress Biotech, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,037,203 | $3.17M | 0.00% | +71,173+7.4% | Added |
| Opaleye Management Inc. | 890,000 | $2.72M | 0.25% | −152,000−14.6% | Reduced |
| Mackenzie Financial Corp | 555,676 | $1.70M | 0.00% | +555,676 | New |
| Gsa Capital Partners LLP | 458,472 | $1.40M | 0.09% | +204,338+80.4% | Added |
| Shikiar Asset Management Inc | 305,469 | $935.0K | 0.24% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 300,521 | $919.9K | 0.00% | +10,266+3.5% | Added |
| BlackRock, Inc. | 224,782 | $687.8K | 0.00% | +27,697+14.1% | Added |
| Two Sigma Investments, LP | 213,786 | $654.2K | 0.00% | +16,961+8.6% | Added |
| Bridgeway Capital Management, LLC | 177,368 | $542.7K | 0.01% | −5,000−2.7% | Reduced |
| Vanguard Fiduciary Trust Co | 166,371 | $509.1K | 0.00% | +23,836+16.7% | Added |